Adaptive Biotechnologies Corp (ADPT) concluded trading on Wednesday at a closing price of $11.98, with 5.41 million shares of worth about $64.77 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 99.67% during that period and on June 25, 2025 the price saw a gain of about 12.49%. Currently the company’s common shares owned by public are about 151.92M shares, out of which, 144.91M shares are available for trading.
Stock saw a price change of 18.15% in past 5 days and over the past one month there was a price change of 34.15%. Year-to-date (YTD), ADPT shares are showing a performance of 269.75% which increased to 99.83% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.26 but also hit the highest price of $10.87 during that period. The average intraday trading volume for Adaptive Biotechnologies Corp shares is 2.09 million. The stock is currently trading 17.36% above its 20-day simple moving average (SMA20), while that difference is up 30.85% for SMA50 and it goes to 68.93% higher than SMA200.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) currently have 151.92M outstanding shares and institutions hold larger chunk of about 94.92% of that.
The stock has a current market capitalization of $1.82B and its 3Y-monthly beta is at 1.80. It has posted earnings per share of -$0.96 in the same period. It has Quick Ratio of 2.82 while making debt-to-equity ratio of 1.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ADPT, volatility over the week remained 5.70% while standing at 2.98% over the month.
Stock’s fiscal year EPS is expected to rise by 21.47% while it is estimated to increase by 24.67% in next year. EPS is likely to grow at an annualized rate of 30.19% for next 5-years, compared to annual growth of -1.51% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Craig Hallum on June 18, 2025 offering a Buy rating for the stock and assigned a target price of $15 to it. Coverage by Goldman stated Adaptive Biotechnologies Corp (ADPT) stock as a Buy in their note to investors on March 21, 2025, suggesting a price target of $9 for the stock. On July 05, 2023, JP Morgan Resumed their recommendations, while on January 05, 2023, Scotiabank Initiated their ratings for the stock with a price target of $15. Stock get an Overweight rating from Piper Sandler on December 21, 2022.
